Global Nuclear Medicine Market Growth, Trends and Forecasts 2018-2023: CAGR to Grow at 12% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 16, 2018--The “Global Nuclear Medicine Market - Segmented by Diagnostics, Therapeutics, Application and Geography - Growth, Trends and Forecasts (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.
The global nuclear medicine market is expected to register a CAGR of 12% during the forecast period, 2018 to 2023.
Increasing incidence of cancer and cardiac ailments are the major drivers for the market. Nuclear medicine shows a huge potential in treating cardiac and cancer diseases. According to a survey by National Cancer Institute, the number of new cases of cancer sites was 460 per 100,000 men and woman per year, while the number of deaths was 176 per 100,000 men and women per year. Cardiology applications will continue to demonstrate strong growth in the market.
Other factors, such as increasing SPECT and PET applications and growing public awareness for healthcare are going to drive the market in the future.
North America is the dominant market for diagnostic radioisotopes. Within North America, the United States is the largest consumer market for radioisotopes, and Canada is the largest producer of Tc-99m.
Key Developments in the MarketApril, 2017: IBA Molecular and Mallinckrodt Nuclear Medicine LLC united to create Curium - a world-class provider in nuclear imaging. October, 2017: Switzerland’s Novartis agreed to pay USD 3.9 billion to take over French nuclear medicines business of Advanced Accelerator Applications, aimed to strengthen its cancer treatment activities.
Companies MentionedCurium Lantheus Medical Imaging Triad Isotopes Siemens Healthineers Bracco Cambridge Isotope Laboratories Inc. Cardinal Health Inc. GE Healthcare Nordion Inc. Fujifilm Holdings Corporation EczacIBAsi-Monrol
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/4ftqvt/global_nuclear?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005732/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Diagnostics,Nuclear Medicine and Radiopharmacology
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL RADIOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 05/16/2018 08:42 AM/DISC: 05/16/2018 08:42 AM